They were removed in the Mayo study because of the FDA hold. Anyone not receiving clinical benefit was removed even if they only had 1 dose.
There have been multiple recent preclinical research conducted at universities that has shown telomerase inhibition (Imetelstat used as the inhibitor) enhances other already approved therapies. Telomerase is expressed by 90% of all cancer. The solid tumor studies the jacosa is referring to were not successful as it appears that telomerase inhibition alone is not effective in solid tumors. Imetelstat may not be a cure for cancer but it has potential as a combo therapy for a broad range of cancers as Janssen further develops Imetelstat. The hope being that Imetelstat can limit the spread of cancer while the standard of care attacks the tumor. I'm not a INCY hater. I hope their therapies are successful but Imetelstat has a completely different mode of action and than Jakafi so they are more likely complimentary than competitive.
More like an extra point. There are plenty of people with money willing to scoop it up at 8.42 and sell it for 8.50.
I wouldn't say Useless or politically corrupt as many of them have served during both Democratic and Republican administrations. However, I do like your idea of using automation but I would imagine that the Fed is already looking at automated data when they make the decisions.
Very strong incentive for Chip to get top dollar from J&J when it is time for the buyout. That is the purpose. It's a win for Chip and a win for the shareholders.
The trial that Irish's husband is in is not open for new enrollment and hasn't been for some time so it's unlikely she would know about new patients.
J&J has already said they anticipate filing an NDA with the FDA in 2017 for IMET. If that's the case then revenue likely in 2018
J&J's repeated mention of IMET as a growth catalyst with blockbuster potential will probably do more to help the PPS than CEO Scarlett's presentation.
Not dropping bombs ? Really ?
US Air Force running out of bombs to fight ISIS
Published December 05, 2015 FoxNews
If you don't want to gamble don't invest in a biotech with zero revenue. I prefer the gamble at $4 as opposed to $20+ with approval.
.... and $4 may seem like a good price compared to what is will be if JNJ opts for the phase 3 MDS pivotal trail in 3 to 4 months.
It doesn't become a phase 3 until Janssen does an internal review of the first 20 patients and gives it a thumbs up. Then it becomes a double blind phase 3.
I have probably held for as long as you have. Started with 50 shares and now sit at 35,000. The light is finally at the end of the tunnel.
Funny how everyone is trying to glom onto the KBIO pop.